1EQA Intermediate Reference Laboratory, STDC, Civil Hospital, Asarwa, Ahmedabad, Gujarat
2Microbiologist, Intermediate Reference Laboratory, STDC, Civil Hospital, Asarwa, Ahmedabad, Gujarat
3Additional Director (Health) and State TB Officer, Gandhinagar, Gujarat
*Corresponding author: Pranav G Patel, M.D. Microbiologist, Intermediate Reference laboratory, STDC, Civil Hospital, Asarwa, Ahmedabad, 380016, Gujarat, Mobile no: 9727722883 E-Mail ID: drpranavpatel09@gmail.com
Online published on 16 March, 2018.
Tuberculosis (TB) is a major threat to world health. A major obstacle to control TB is the emergence of mycobacterial resistance to anti-tuberculous chemotherapy.
Total 145 MDR isolates were included in this study to determine the DST of 1st and 2nd line agents (levofloxacin 1.5, moxifloxacin 2.0, kanamycin 2.5 and capreomycin 2.5, ethambutol 5.0, ethionamide 5.0, PAS 4.0, clofazamine 1.0, linezolid 1.0 & pyrazinamaide 100) by MGIT 960.
13.7% isolates were sensitive to all 10 drugs. Fluroquinolone (levofloxacin 1.5 & moxifloxacin 2.0) resistance was 11.7%, Aminoglycoside resistant (kanamycin 2.5 and capreomycin 2.5) resistance was 6.2%. 2.7% isolates were XDR. One MDR isolate was resistant to all studied drugs.
Due to emergence of resistance to 2nd line drugs, there is a need of DST guided treatment in order to develop efficient regimens for appropriate treatment of individual cases.
MDR, XDR, MGIT, 1st line DST, 2nd line DST
